Clinical efficacy of immunotherapy plus targeted therapy combined with local treatment for unresectable hepatocellular carcinoma / 中华消化外科杂志
Chinese Journal of Digestive Surgery
;
(12): 25-28, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-990602
ABSTRACT
Immunotherapy combined with targeted therapy can benefit the survival of patients with unresectable hepatocellular carcinoma. Atezolizumab combined with bevacizumab has achieved remarkable efficacy in patients with advanced hepatocellular carcinoma, but the efficacy of conversion therapy in patients with unresectable hepatocellular carcinoma still needs more evidences. The authors report the clinical efficacy of a case of unresectable hepatocellular carcinoma with hepatitis B virus related liver cirrhosis who was treated with immunotherapy plus targeted therapy combined with local treatment. Results show a good effect in patient without tumor recurrence after postoperative 9 months.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Digestive Surgery
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS